Compare BTBT & SLDB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BTBT | SLDB |
|---|---|---|
| Founded | 2015 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 569.7M | 498.6M |
| IPO Year | 2017 | 2017 |
| Metric | BTBT | SLDB |
|---|---|---|
| Price | $1.54 | $8.19 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 11 |
| Target Price | $6.00 | ★ $16.36 |
| AVG Volume (30 Days) | ★ 16.5M | 1.0M |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 34.97 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $113,560,320.00 | $8,094,000.00 |
| Revenue This Year | $89.54 | N/A |
| Revenue Next Year | $48.40 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 5.10 | N/A |
| 52 Week Low | $1.25 | $2.45 |
| 52 Week High | $4.55 | $8.87 |
| Indicator | BTBT | SLDB |
|---|---|---|
| Relative Strength Index (RSI) | 52.80 | 59.74 |
| Support Level | $1.25 | $5.16 |
| Resistance Level | $2.43 | $8.47 |
| Average True Range (ATR) | 0.10 | 0.62 |
| MACD | 0.03 | 0.06 |
| Stochastic Oscillator | 87.50 | 72.18 |
Bit Digital Inc is engaged in the Bitcoin mining business, Ethereum staking activities and specialized cloud-infrastructure services for artificial intelligence applications through its wholly owned subsidiaries. Its mining platform operates with the primary intent of accumulating bitcoin which may sell for fiat currency from time to time depending on market conditions. The Company has four reportable segments: digital asset mining, cloud services, colocation services, and ETH Staking. It generates majority of its revenue from digital asset mining.
Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.